-
Juno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption
Wednesday, July 13, 2016 - 8:55am | 276Read More...Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by nearly 25 percent to $34.50 ahead of Wednesday's market open. The biopharma company focused on the treatment of cancer announced after Tuesday's market close that the U.S. Food and Drug Administration removed a clinical hold...
-
Nexvet Biopharma Gains 15%, Company Reports Positive Results From Pilot Field Study
Thursday, May 26, 2016 - 8:58am | 259Read More...Shares of Nexvet Biopharma plc (NASDAQ: NVET), a nano-cap clinical-stage biopharmaceutical company that focuses on developing therapies for companion animals, surged higher by more than 15 percent early Thursday morning. Nexvet Biopharma reported results from its NV-02 pilot field study in cats...
-
Here's Why OXiGENE Surged 65% Early Tuesday Morning
Tuesday, May 24, 2016 - 9:10am | 307Read More...Shares of OXiGENE Inc (NASDAQ: OXGN), a nano-cap biopharmaceutical company that focuses on the development of vascular disrupting agents for the treatment of cancer, surged higher by more than 65 percent early Tuesday morning. Investors and traders reacted to OXiGENE's announcement that the "...
-
Report: Medivation Committed To Selling Itself
Tuesday, May 10, 2016 - 8:42am | 238Read More...Medivation Inc (NASDAQ: MDVN) had an offer on the table to be acquired by Sanofi SA (ADR) (NYSE: SNY) for $9.3 billion, or $52.50 per share. Medivation rejected Sanofi's buyout offer and argued that its own business plan and strategy will ultimately deliver superior shareholder growth. However, the...
-
Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains
Monday, April 18, 2016 - 1:03pm | 239Read More...Immunomedics, Inc. (NASDAQ: IMMU), a clinical stage biopharmaceutical company that focuses on the treatment of cancer, presented data at the 2016 American Association for Cancer Research's annual meeting. Immunomedics said in a corresponding press release that its presentation focused on...
-
PTC Therapeutics Spikes 40% After Translarna Update In England
Friday, April 15, 2016 - 1:45pm | 364Read More...Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company that focuses on therapeutics that target post-transcriptional control processes, surged higher by more than 40 percent Friday afternoon. Investors and traders were reacting to the company's announcement that the...
-
Pain Therapeutics Gains 7%, FDA Has Accepted Company's Remoxy For Review
Wednesday, April 13, 2016 - 11:32am | 179Read More...Shares of Pain Therapeutics, Inc. (NASDAQ: PTIE), a micro-cap biopharmaceutical company whose lead drug candidate, REMOXY, is used for the treatment of moderate to severe pain. Pain Therapeutics announced after Tuesday's market close the U.S. Food and Drug Administration determined that its...
-
Repros Therapeutics Surges 60% Following Encouraging Study Results
Wednesday, April 13, 2016 - 7:26am | 163Read More...Shares of Repros Therapeutics Inc (NASDAQ: RPRX), a nano-cap biopharmaceutical company that focuses on the treatment of hormonal and reproductive system disorders, is surging higher by 60 percent. Repros Therapeutics reported after Tuesday's close that patients receiving 6 and 12 mg doses...
-
Viking Therapeutics Gains 5% As Company Highlights Positive Data From A Phase 1b Clinical Trial
Monday, April 11, 2016 - 10:41am | 312Read More...Shares of Viking Therapeutics Inc (NASDAQ: VKTX), a clinical stage biopharmaceutical company that focuses on the treatment of metabolic and endocrine disorders, gained more than 5 percent on Monday. Viking Therapeutics highlighted positive data from a phase 1b clinical trial of VK2809 in...
-
Amicus Therapeutics Gains 3% On Favorable EU Medicines Recommendation
Friday, April 1, 2016 - 2:37pm | 392Read More...Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD), a bio-pharmaceutical company that focuses on the treatment of rare and orphan diseases, were trading higher by 3 percent Friday afternoon. Amicus Therapeutics announced earlier in the day that the European Committee for Medicinal Products for...
-
Genocea Biosciences Spikes 30% After Positive Data From Phase 2 Trial
Thursday, March 31, 2016 - 10:11am | 217Read More...Shares of Genocea Biosciences Inc (NASDAQ: GNCA), a biopharmaceutical company that focuses on diseases with unmet needs, surged higher by more than 30 percent on Thursday. Genocea Biosciences announced earlier in the morning data from a 12-month Phase 2 study evaluating its lead candidate GEN...
-
MediciNova Gains 6% Following Positive Mention In Medical Journal
Thursday, March 31, 2016 - 7:55am | 194Read More...Shares of MediciNova, Inc. (NASDAQ: MNOV), a biopharmaceutical company that focuses on the treatment of serious diseases with unmet medical needs, were trading higher by more than 6 percent early Thursday morning. MediciNova announced after Wednesday's close that the medical journal Drug...
-
Keryx Biopharmaceuticals Surges 20% Following Positive Kidney Disease Drug Data
Tuesday, March 29, 2016 - 8:54am | 241Read More...Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a biopharmaceutical company that focuses on the treatment of renal diseases, gained more than 20 percent early Tuesday morning. Keryx Biopharmaceuticals announced positive top-line results from its pivotal Phase 3 study of ferric citrate for the...
-
Alder Biopharma Surged 60% Following Phase 2 Results
Monday, March 28, 2016 - 11:15am | 272Read More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR), a clinical-stage biopharmaceutical company, surged higher by nearly 60 percent on Monday. Alder Biopharmaceuticals announced earlier in the morning positive top-line data from 2 clinical trials which studied its ALD403 product, an antibody...
-
FDA Places Cara Therapeutics' Pain Trial On Clinical Hold, Shares Plunge 42%
Friday, February 26, 2016 - 8:35am | 237Read More...Cara Therapeutics Inc (NASDAQ: CARA), a clinical-stage bio-pharmaceutical company that focuses on the development of chemical entities to alleviate pain and pruritus, announced a business update after Thursday's market close. Cara Therapeutics said that the U.S. Food and Drug Administration has...
